Matches 1 - 50 out of 60 1 2 >


Match Document Document Title
US20070292511 Duloxetine hydrochloride delayed release formulations  
Delayed release formulations of duloxetine hydrochloride and methods for its manufacture are described. A preferred formulation includes an inert core, a drug layer comprising duloxetine...
US20060134210 Solid dosage form comprising proton pump inhibitor and suspension made thereof  
A solid, rapidly gelling oral pharmaceutical dosage form, as well as an aqueous formulation prepared thereof, comprising a) an acid sensitive proton pump inhibitor as active ingredient distributed...
US20080166405 Abuse-resistant oral dosage forms and method of use thereof  
An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but...
US20050266079 Process for making aqueous coated beadlets  
The present invention is directed to application of novel process conditions for aqueous coating techniques of water soluble active agents, and its application to production of sustained release...
US20130209561 ABUSE-RESISTANT OPIOID DOSAGE FORM  
We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.
US20070275060 Extended release solid pharmaceutical composition containing carbidopa and levodopa  
The invention provides a compressed tablet that provides a extended release tablet containing a extended release form of carbidopa and a extended release form of levodopa. The tablet optionally...
US20050089573 Oral pharmaceutical formulation containing ibandronate  
The invention is directed to well-tolerated pharmaceutical compositions for oral application, containing ibandronate or a physiologically tolerable salt thereof as active substance, the...
US20050048117 Use of methylnaltrexone and related compounds  
A composition for preventing or treating the opioid induced side effect, inhibition of gastrointestinal motility is disclosed. The composition comprises methylnaltrexone or another quaternary...
US20060078615 Bilayer tablet of telmisartan and simvastatin  
A bilayer tablet comprises a first layer formulated for instant release of the angiotensin II receptor antagonist telmisartan from a dissolving tablet matrix and a second layer formulated for...
US20050042277 Pharmaceutical compositions having a swellable coating  
A pharmaceutical dosage form containing a pharmaceutical active that is not stable in the presence of acid comprises a core containing the active and a disintegrant, a swellable coating...
US20100323011 PHARMACEUTICAL COMPOSITIONS OF A COMBINATION OF METFORMIN AND A DIPEPTIDYL PEPTIDASE-IV INHIBITOR  
Disclosed are pharmaceutical compositions comprising fixed-dose combinations of an extended-release form of metformin, or a pharmaceutically acceptable salt thereof, coated with an...
US20100291204 COMBINATION OF A LONG-ACTING HYPNOTIC AGENT AND A SHORT-ACTING HYPNOTIC AGENT AND THERAPEUTIC USE THEREOF  
The invention relates to the combination of: a short-acting hypnotic agent which is selected from among a modulators of receptors GABA-A, a benzodiazepine, a phenothiazine, a melatonin derivative...
US20100183713 GASTROINTESTINAL-SPECIFIC MULTIPLE DRUG RELEASE SYSTEM  
The present invention provides compositions and methods for the multiple release of a drug in the gastrointestinal tract of a subject through the use of an oral multiple drug release system. The...
US20050147677 Systems, methods and apparatuses for manufacturing dosage forms  
Systems, methods and apparatuses for manufacturing dosage forms, and to dosage forms made using such systems, methods and apparatuses are provided. Novel compression, injection molding, and...
US20060057201 Multicomponent pharmaceutical dosage form  
A multi-component pharmaceutical dosage form suitable for retaining drug substance can be released to provide a controlled drug release profile in the gastro intestinal environment, characterized...
US20090041840 Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration  
A novel sleep regulating pharmaceutical formulation is introduced, typically implementing two principal drugs having actions which are reversive to one another, yet incorporated into a unitary...
US20110142933 Controlled Release Dosage Form of Tacrolimus  
A controlled release dosage form of tacrolimus, comprising a solid dispersion of tacrolimus, wherein a controlled release base, which is selected from the group consisting of a water-soluble...
US20050019405 Controlled release composition  
A composition for controlled delivery of at least one active substance into an aqueous medium by erosion at a preprogrammed rate of at least one surface of the composition, comprising a matrix...
US20050202088 Pharmaceutical composition having a delayed active substance release, and method for the preparation thereof  
A pharmaceutical composition with sustained drug release is described which is obtainable by a specific compaction process wherein organic solvents and water are not required and which is...
US20050214369 Lecithin-containing granular compositions and methods of their preparation  
Methods of preparing granular compositions containing lecithin, preferably as a major or sole ingredient, are described. Granular lecithin-containing compositions are also described and can be...
US20070243254 NOVEL DRUG COMPOSITIONS AND DOSAGE FORMS OF TOPIRAMATE  
The present invention is directed to novel drug compositions and dosage forms comprising said drug compositions. The drug compositions of the present invention comprise a pharmaceutical agent and...
US20070036860 Treatment of allergic conditions  
Orally administered sodium cromoglycate has been found to be effective in the treatment of allergic conditions such as asthma, general food allergies, ulcerative colitis, atopic eczema, chronic...
US20050208154 Pharmaceutical compositions containing lithium carbonate  
Once daily pharmaceutical compositions containing lithium carbonate in the form of coated granules.
US20050025829 Controlled drug release tablets  
A pharmaceutical composition in the form of a perforated tablet comprising one or more than one enteric polymer and a drug, where the enteric polymer is substantially hydrophobic and substantially...
US20150072005 ASPIRIN FORMULATION FOR INCREASED EFFICACY  
Provided are methods for enhancing the efficacy of aspirin. Also provided are methods for reducing pain or preventing or treating heart attack, stroke or blood clot in a subject in need thereof....
US20110123613 EXTENDED-RELEASE DOSAGE FORM  
Provided are pharmaceutical formulations comprising sustained release particles each having an inner core bead comprising an active pharmaceutical ingredient an intermediate coating substantially...
US20050089571 Pharmaceutical formulation for the active ingredient budesonide  
The invention relates to a pharmaceutical formulation containing essentially a) an inner layer which can optionally be applied to a core, with the active substance budesonide, bound with a binding...
US20050042290 Controlled release pharmaceutical formulation containing venlafaxine  
A solid controlled release pharmaceutical formulation for once daily administration comprises a core comprising venlafaxine, polyvinylpyrrolidone, a low viscosity hydrophilic polymer and a high...
US20140004189 MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS MEMANTINE  
Modified release pharmaceutical compositions of memantine or pharmaceutically acceptable salts thereof are described. The compositions of invention are stable, possess improved formulation...
US20100172983 Pharmaceutical Compositions for the Coordinated Delivery of Naproxen and Esomeprazole  
The present disclosure is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The...
US20070184111 Hybrid tablet  
A hybrid tablet and method are provided. The tablet may have an inner core and an outer layer. The outer layer includes a first agent, the outer layer having a first dissolution rate. The inner...
US20070218135 Sustained release matrix pharmaceutical composition  
A sustained release pharmaceutical composition in solid dosage form is provided comprising (a) a therapeutically effective amount of one or more active pharmaceutical agents; (b) a first high...
US20150079169 CONTROLLED DOSING OF CLOPIDOGREL WITH GASTRIC ACID INHIBITION THERAPIES  
The present invention provides for novel formulations of clopidogrel in combination with proton pump inhibitors (PPI) and optionally with NSAIDs, for use as improved antiplatelet therapies in...
US20050089572 Controlled release drug delivery system of pravastatin  
The present invention relates to an oral drug delivery system comprising pravastatin or its pharmaceutically acceptable salts such that the system provides enhanced stability in the acidic...
US20050226929 Controlled release opioid analgesic formulation  
A pharmaceutical sustained release formulation for opioid analgesics which can be administered every 12 hours for control of pain in patients suffering from chronic pain.
US20050084531 Tablet with aqueous-based sustained release coating  
A tablet core containing a water-soluble, preferably highly water-soluble, active ingredient is coated for sustained release with an aqueous-based coating of an ethyl acrylate-methyl methacrylate...
US20070036859 Sustained release antihistamine and decongestant composition  
A controlled-release, non-sedating antihistamine and decongestant composition which provides a 24-hour decongestant dissolution profile using standard ungranulated xanthan gum as the sole...
US20070036858 Drug delivery system for topical administration  
This invention is directed to new drug delivery systems (SMS packaging™) and uses thereof, of freshly prepared, effective, high concentrated, hygienic pharmaceutical compositions. The new delivery...
US20100285125 DELIVERY SYSTEM FOR POORLY SOLUBLE DRUGS  
The present invention relates to an oral drug delivery system for poorly soluble drugs, which can provide sustained near zero order release of poorly water soluble drugs from erodible matrix...
US20070248670 TOLTERODINE BEADS  
Controlled release tolterodine beads are formed of a sugar core, an innermost sealcoat layer comprising HPMC, a tolterodine drug layer, and an outer control release layer. The thickness of the...
US20070212417 Compressible resilient granules and formulations prepared therefrom  
Methods and compositions having resilient, self-adhered granules are disclosed and described. In one embodiment, a resilient, self-adhering granule, which includes a combination of a...
US20070231385 Controlled Release Pharmaceutical Composition and a Process for Preparing the Same  
A three-drug antiretrovial pharmaceutical composition having a selective combination of a controlled release active formulation and an immediate release active formulation for once daily...
US20090169622 DELAYED-RELEASE ORAL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF COLONIC DISORDERS  
A timed or delayed release oral composition delivery system for the treatment of colonic disorders and diseases is provided. According to one aspect, a delayed release oral pharmaceutical...
US20060073205 Controlled release granules comprising porous silica core  
The present invention relates to controlled release granules for medical use comprising a drug loaded porous silica particle, and at least one layer of a controlled release coating material,...
US20130078304 CONTROLLED RELEASE FORMULATION FOR TREATING SLEEP DISORDERS  
The invention relates to a controlled-release formulation for preventing and/or treating sleep disorders comprising Zaleplon or a pharmaceutically acceptable salt thereof in immediate release form...
US20110111022 PHARMACEUTICAL FORMULATION  
The present invention provides a pharmaceutical formulation comprising a compartment containing a rennin inhibitor as a pharmacologically active ingredient, and a compartment having an...
US20070218134 Compositions Comprising Organic Compounds  
The present invention relates to pharmaceutical compositions for sustained release comprising as active ingredient an HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof,...
US20060073206 Coating meltable substances and substance mixtures  
The invention relates to a method for coating meltable substances or substance mixtures. A melt of the substance (mixture) drips into a melt of the coating agent(s) where it solidifies at least on...
US20050106253 Pharmaceutical pellets comprising tamsulosin  
Tamsulosin pellets having an advantageous release profile are formed. The pellets have an enteric coating and release less than 25% of the tamsulosin in two hours in SGF.
US20070141149 Controlled-release pharmaceutical formulation  
In the present invention, a new pharmaceutical formulation with controlled release of the freely water soluble low-dose active substance used for at the most once daily administration is...

Matches 1 - 50 out of 60 1 2 >